Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs, has a prognosis that is influenced by a number of ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

The company is advancing multiple trials, including a human abuse potential trial, a Phase IIb study for chronic cough in idiopathic pulmonary fibrosis (IPF), and a Phase IIa trial for refractory ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Three major industry organisations are planning to merge and form a single body to represent the property sector.

The Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property Forum (IPF) ...

The boards of three property industry groups are beginning talks to merge. The British Property Federation (a cheerleader for Build To Rent), the Association of Real Estate Funds and the Investment ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

The winner of the Established Business to Business category in The Australian Financial Review Customer Champions list 2024, ...